A Hedge Fund Rolls the Dice on Ultragenyx

A Hedge Fund Rolls the Dice on Ultragenyx

FOIAengine: Sofinnova Bet on Drug FDA Approved Last Week  Shares of Ultragenyx Pharmaceutical Inc. rose 16 percent September 17 after the Food and Drug Administration approved Fayuvi, its gene therapy for Sanfilippo syndrome Type A, a rare and devastating genetic...